The closing price of Sangamo Therapeutics Inc (NASDAQ: SGMO) was $0.56 for the day, down -2.35% from the previous closing price of $0.57. In other words, the price has decreased by -$0.0135 from its previous closing price. On the day, 1103948 shares were traded. SGMO stock price reached its highest trading level at $0.5838 during the session, while it also had its lowest trading level at $0.5411.
Ratios:
Our analysis of SGMO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on November 03, 2023, Downgraded its rating to Sector Perform and sets its target price to $2 from $6 previously.
On April 28, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $5 to $1.50.
Wedbush Upgraded its Neutral to Outperform on February 27, 2023, while the target price for the stock was maintained at $16.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 26 ’23 when BIOGEN INC. sold 6,000,000 shares for $0.50 per share. The transaction valued at 3,000,000 led to the insider holds 17,652,466 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 114.30M and an Enterprise Value of 71.40M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.65 while its Price-to-Book (P/B) ratio in mrq is 1.21. Its current Enterprise Value per Revenue stands at 0.41 whereas that against EBITDA is -0.74.
Stock Price History:
Over the past 52 weeks, SGMO has reached a high of $1.80, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is 0.7872, while the 200-Day Moving Average is calculated to be 0.7669.
Shares Statistics:
SGMO traded an average of 2.39M shares per day over the past three months and 2.49M shares per day over the past ten days. A total of 203.67M shares are outstanding, with a floating share count of 180.11M. Insiders hold about 11.57% of the company’s shares, while institutions hold 43.08% stake in the company. Shares short for SGMO as of Mar 15, 2024 were 10.88M with a Short Ratio of 4.56, compared to 9.73M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.08% and a Short% of Float of 7.08%.
Earnings Estimates
The firm’s stock currently is rated by 8 analysts. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.27, while EPS last year was $0.12. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.08 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.23 and -$0.77 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.27, with 8 analysts recommending between $0.28 and -$0.64.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $11.3M to a low estimate of $2M. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $157.96M, an estimated decrease of -95.80% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $8.24M, a decrease of -44.40% over than the figure of -$95.80% in the same quarter last year. There is a high estimate of $17.8M for the next quarter, whereas the lowest estimate is $2M.
A total of 7 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $95M, while the lowest revenue estimate was $13.8M, resulting in an average revenue estimate of $45.88M. In the same quarter a year ago, actual revenue was $176.23M, down -74.00% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $79.01M in the next fiscal year. The high estimate is $229M and the low estimate is $26.4M. The average revenue growth estimate for next year is up 72.20% from the average revenue estimate for this year.
